Reuters logo
BRIEF-Cerenis Therapeutics announces initiation of Phase 1 clinical study with CER-209 in NAFLD and NASH
April 18, 2017 / 6:17 AM / in 7 months

BRIEF-Cerenis Therapeutics announces initiation of Phase 1 clinical study with CER-209 in NAFLD and NASH

April 18 (Reuters) - Cerenis Therapeutics Holding SA:

* Announces initiation of Phase 1 clinical study with CER-209 in NAFLD and NASH Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below